Your browser doesn't support javascript.
loading
Evaluating the druggability of TrmD, a potential antibacterial target, through design and microbiological profiling of a series of potent TrmD inhibitors.
Wilkinson, Andrew J; Ooi, Nicola; Finlayson, Jonathan; Lee, Victoria E; Lyth, David; Maskew, Kathryn S; Newman, Rebecca; Orr, David; Ansell, Keith; Birchall, Kristian; Canning, Peter; Coombs, Peter; Fusani, Lucia; McIver, Ed; Pisco, João; Ireland, Philip M; Jenkins, Christopher; Norville, Isobel H; Southern, Stephanie J; Cowan, Richard; Hall, Gareth; Kettleborough, Catherine; Savage, Victoria J; Cooper, Ian R.
Afiliación
  • Wilkinson AJ; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK. Electronic address: Andrew.Wilkinson@infextx.com.
  • Ooi N; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Finlayson J; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Lee VE; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Lyth D; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Maskew KS; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Newman R; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Orr D; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Ansell K; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Birchall K; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Canning P; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Coombs P; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Fusani L; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • McIver E; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Pisco J; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Ireland PM; CBR Division, Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, UK.
  • Jenkins C; CBR Division, Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, UK.
  • Norville IH; CBR Division, Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, UK.
  • Southern SJ; CBR Division, Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, UK.
  • Cowan R; Leicester Institute of Structural and Chemical Biology and Department of Molecular and Cell Biology, Henry Wellcome Building, University of Leicester, Leicester LE1 7RH, UK.
  • Hall G; Leicester Institute of Structural and Chemical Biology and Department of Molecular and Cell Biology, Henry Wellcome Building, University of Leicester, Leicester LE1 7RH, UK.
  • Kettleborough C; LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK.
  • Savage VJ; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
  • Cooper IR; Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
Bioorg Med Chem Lett ; 90: 129331, 2023 06 15.
Article en En | MEDLINE | ID: mdl-37187252
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: ARNt Metiltransferasas / Metiltransferasas Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: ARNt Metiltransferasas / Metiltransferasas Idioma: En Año: 2023 Tipo del documento: Article